Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Terra Magnum Capital Partners (“TMCP”)

Investor type Private Equity Firm

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 11
Average round size
info
The average size of a deal this fund participated in
$90M
Portfolio companies 10
Rounds per year 1.83
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.09
Exits 2
Key employees 1
Stages of investment
Private Equity

Areas of investment

  • Biotechnology
  • Medical
  • Health Care
  • Life Science
  • Pharmaceutical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Terra Magnum Capital Partners (“TMCP”):
Typical Co-investors
Terra Magnum Capital Partners (“TMCP”) is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Terra Magnum Capital Partners (“TMCP”):

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Walking Fish Therapeutics

Biotechnology
Life Science
$23M16 Feb 2022 San Francisco, California, United States

Maze Therapeutics

Biotechnology
Therapeutics
$190M10 Jan 2022 Redwood City, California, United States

ShouTi

Biotechnology
Health Care
Medical
Pharmaceutical
Product Research
$100M20 Oct 2021 Shanghai, China

Senda Biosciences

Biotechnology
Life Science
$55M10 Jun 2021 Cambridge, Massachusetts, United States

Arcellx

Biopharma
Health Care
Pharmaceutical
$115M13 Apr 2021 Maryland, United States

Flame Biosciences

Biotechnology
Health Care
Medical
$100M30 Sep 2020 New York, United States

RNAimmune

Biotechnology
Life Science
$2M24 Aug 2020 Maryland, United States

Erasca

Biotechnology
Emergency Medicine
Health Care
Life Science
$200M27 Apr 2020 San Diego, California, United States

Immunocore

Biotechnology
Medical
Pharmaceutical
$130M02 Mar 2020 England
News
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Terra Magnum Capital Partners (“TMCP”)?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: